JP2016088926A5 - - Google Patents

Claims (16)

An anti-inflammatory agent comprising an IKAROS (IKZF1) inhibitor. The anti-inflammatory drug according to claim 1, wherein the IKAROS inhibitor is selected from the group consisting of PGE2, anti-IKAROS siRNA, and anti-IKAROS antibody. The anti-inflammatory agent according to any one of claims 1 to 2, wherein the anti-inflammatory agent targets epithelial tissue. The anti-inflammatory drug according to any one of claims 1 to 3, wherein the inflammation is inflammation involving an epithelium caused by IKAROS. The anti-inflammatory agent according to any one of claims 1 to 4 , which is a topical administration agent. The anti-inflammatory drug according to any one of claims 1 to 5, wherein the anti-inflammatory drug is for treatment or prevention of inflammation in skin or mucosal tissue. The following steps (1) to (3):
(1) contacting a cell containing a nucleic acid encoding a reporter protein under the control of the IKAROS gene or the transcriptional regulatory region of the gene of interest with a test substance;
(2) a step of measuring the expression level of an IKAROS gene or an IKAROS protein or reporter protein in the cell; and (3) an IKAROS gene or an IKAROS protein or a reporter protein as compared with a case where measurement is performed in the absence of a test substance. A method for screening an anti-inflammatory substance, comprising a step of selecting a test substance having a reduced expression level of as a candidate for an anti-inflammatory substance.   A method for screening an anti-inflammatory substance, which comprises contacting an IKAROS and a test substance and selecting a test substance capable of binding to IKAROS as a candidate for the anti-inflammatory substance. The following steps (1) to (3):
(1) a step of contacting a target cell of an inflammatory disease with a test substance in the presence and absence of IKAROS;
(2) a step of measuring the degree of inflammatory reaction in the cells under each condition; and (3) suppressing the inflammatory reaction in the presence of IKAROS as compared to the case of measuring in the absence of the test substance. A method for screening an anti-inflammatory substance, comprising a step of selecting a test substance that did not suppress an inflammatory reaction in the absence of IKAROS as a candidate for a substance that inhibits the function of IKAROS and exhibits an anti-inflammatory action.   The method according to claim 9, wherein an inflammatory response is induced by stimulation with polyI: C, interleukin-Iα (IL-1α), tumor necrosis factor (TNF) α or H 2 O 2.   11. A method according to any one of claims 7, 9 or 10, wherein the cells comprise epithelial cells. The method according to any one of claims 7 to 11, wherein the inflammation is inflammation involving epithelium caused by IKAROS. A composition for increasing or inducing IKAROS gene expression, comprising polyI: C. An isolated cell in which expression of the IKAROS gene is increased or induced. An inflammation model animal in which expression of the IKAROS gene is increased or induced. The inflammation model animal according to claim 15, wherein the inflammation model animal has cell infiltration in at least one selected from the group consisting of skin tissue and mucosal tissue.